Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Op...(es said Jim Mazzo chairman and chief ex...)

Date:1/12/2009

es," said Jim Mazzo, chairman and chief executive officer, AMO, who will be remaining with Abbott as president, AMO. "Joining forces with Abbott will fortify our position as a global ophthalmic medical device leader and enhance our ability to serve eye care practitioners and patients around the world."

Global Growth in Vision Correction

Population growth and demographic shifts are increasing demand for advanced vision care technologies across all geographies and age groups. For example, about 60 percent of people older than 60 have cataracts, which are the leading cause of vision loss among this age group. It is estimated that 700 million people globally are 60 years or older, and that number is expected to grow to one billion over the next decade.

"With AMO, Abbott will immediately become a global leader in vision," said John M. Capek, executive vice president, Medical Devices, Abbott. "The business is poised for long-term growth, driven by advances in refractive surgery technologies, including LASIK, and an aging global population."

Financial Terms

Under the terms of the agreement, Abbott will commence a tender offer by Jan. 26, 2009, to purchase all outstanding shares of AMO at $22 per share. The tender offer is conditioned on the tender of a majority of the outstanding shares of AMO's common stock on a fully diluted basis. The $2.8 billion estimated value of the transaction is based on AMO's approximately 62 million fully diluted shares outstanding, plus estimated net debt at the time of closing. The Boards of Directors of AMO and Abbott have approved the transaction. Abbott expects the transaction to be neutral to ongoing earnings per share in 2009, and accretive beginning in 2010, both before one-time transaction-related costs, which will be provided at a later date.

The transaction is subject to customary closing conditions, including antitrust
'/>"/>

SOURCE Abbott Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Abbott Announces Earnings Guidance for 2009
2. Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences
3. Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis
4. Abbotts XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award
5. Abbott Hosts Conference Call for Third-Quarter Earnings
6. Abbott to Present at UBS Best of Americas Investment Conference
7. Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology
8. Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
9. Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
10. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
11. Abbott Invests Additional $20M in Isis Subsidiary Ibis Biosciences